High-throughput multi-analyte Luminex profiling implicates eotaxin-1 in ulcerative colitis.

Area of Science:

• Gastroenterology
• Immunology
• Biomarker Discovery

Background:

• Inflammatory bowel disease (IBD) requires new therapeutic targets and methods for therapy optimization.
• Multi-analyte protein assays, such as Luminex technology, offer high-throughput analysis of cytokines and chemokines.

Purpose of the Study:

• To assess the utility of Luminex-based multiplex assays for cytokine/chemokine profiling in ulcerative colitis (UC).
• To identify potential biomarkers and therapeutic targets in UC pathogenesis.

Main Methods:

• Prospective study of serum and colon biopsies from 137 UC patients and 38 controls.
• Luminex-based multiplex testing of 42 analytes in serum and tissue.
• Correlation of cytokine/chemokine levels with disease activity (Mayo Disease Activity Index) and histology.
• Validation of eotaxin-1 levels using real-time PCR and murine colitis models.

Main Results:

• Eotaxin-1 and G-CSF were elevated in serum of active UC patients compared to controls.
• Thirteen cytokines/chemokines were increased in UC tissues; eotaxin-1 was elevated across all disease activity levels in both serum and tissue.
• Tissue eotaxin-1 correlated with disease activity index and eosinophil counts.
• Elevated tissue eotaxin-1 was observed in multiple murine colitis models, but not in H. pylori infection.

Conclusions:

• Eotaxin-1 is implicated as an etiological factor and potential therapeutic target in UC.
• Luminex-based assays are valuable for assessing IBD pathogenesis.
• These assays can aid in selecting patients for anti-cytokine/chemokine therapies.